News | Robotic Systems | March 31, 2022

National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders

Stereotaxis robotic technology now in use in 25 countries.

Stereotaxis’ Genesis Robotic Magnetic Navigation (RMN) system

April 1, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, has announced that Poland’s National Institute of Cardiology, the leading clinical center of cardiology and cardiac surgery in Warsaw, has established the first robotic electrophysiology program in the country with Stereotaxis’ Genesis Robotic Magnetic Navigation (RMN) system. The National Institute of Cardiology is the only hospital in Poland offering advanced robotic technology to improve the minimally invasive treatment of heart arrhythmias.

A 2019 study reported that 3.8% of Warsaw residents aged 20-65 had an arrhythmia with the prevalence of arrhythmia increasing to 18.6% for those over age 65. By this estimate, over 2 million individuals in Poland may suffer from arrhythmias.

“We are proud to pioneer advanced medical technology in Poland and to be one of the first three hospitals in Europe using the advanced Genesis RMN technology to improve the care of patients who suffer from arrhythmias,” said Prof. dr. hab. n. med. Lukasz Szumowski, director of the National Institute of Cardiology.

The Genesis RMN system introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, certain arrhythmias can significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

“We are proud that we can bring this new and innovative robotic technology to Poland,” says Leszek Piątek, Vice President of Consultronix, distributor of advanced medical equipment in Poland. “We are confident it will have a significant impact on improving cardiology patient care in Poland and will provide a new quality of electrophysiology treatments. Providing the best medical solutions is and always will be the goal of Consultronix.”

“We are delighted to partner with the National Institute of Cardiology and Consultronix to pioneer the benefits of Robotic Magnetic Navigation in Poland,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to supporting their efforts to improve patient care and advance clinical science.”


Related Content

News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
News | EP Lab

September 22, 2023 — Innovative Health, Inc. launched a new educational initiative and free online tool to help hospital ...

Home September 22, 2023
Home
News | EP Lab

August 17, 2023 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home August 17, 2023
Home
News | EP Lab

March 28, 2023 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home March 28, 2023
Home
Subscribe Now